Anastasia Fedorova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anastasia Fedorova has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Galina A. Klyasova
National Medical Research Center for Hematology, Ministry of Health of Russia
9 shared publications - Larisa A. Kuzmina
National Medical Research Center for Hematology
5 shared publications - Elena Parovichnikova
National Medical Research Center of Hematology
4 shared publications - I. N. Frolova
National Medical Research Center for Hematology, Ministry of Health of Russia
4 shared publications - Mobil Akhmedov
PA Gertsen Moscow Oncology Research Institute, branch of the NMRC of Radiology, 3 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284
4 shared publications - Mikhail Yu. Drokov
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
3 shared publications
Latest Publications
- Open Access
- 28 December 2025
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 27 (3) , 359-368
Vancomycin-resistant Enterococcus faecium in hematology: susceptibility to antimicrobial agents and clonal diversity
Objective. To study the antimicrobial resistance and clonal diversity of vancomycin-resistant E. faecium in hematology. Materials and Methods. Vancomycin-resistant E. faecium (VR-E. faecium) isolated from the blood culture of patients in six hospitals of Russia (2005–2023). Antimicrobial susceptibility of VR-E. faecium were determined by serial broth micro dilution was (CLSI, 2024), to tigecycline assessed according to EUCAST, 2025. Vancomycin-resistance genes (vanA, vanB) in VR-E. faecium were detected by multiplex PCR. Genotyping of VR-E. faecium was performed by MLST. Results. During the study period, 465 strains of E. faecium were isolated from blood culture, of which 122 (26.3%) were VR-E. faecium. The detection rate of VR-E. faecium increased from 13.1% (2005– 2011) to 59% (2018–2023, p = 0.0015). The majority of VR-E. faecium had the vanA genes (79.5%), while the vanB genes were detected in 20.5% of VR-E. faecium. All VR-E. faecium were susceptibledose dependent to daptomycin. The daptomycin MIC value of 4 μg/ml was determined in 16.4% of VRE. faecium and increased to 20.7% in 2018–2023. One (0.8%) VR-E. faecium strain was resistant to linezolid. All VRE. faecium isolates remained susceptible to tigecycline. A total of 24 sequence types (STs) belonging to clonal complex CC17 were detected. The predominant sequence types were ST80 (30.3%), ST17 (18.9%), and ST78 (13.1%). In 2023, a new ST2470 was registered in the pubMLST database. From 2018 to 2023, the proportion of ST80 increased to 62.1%, while ST17 and ST78 decreased to 13.8% and 5.2% respectively. vanA VR-E. faecium significantly more often belonged to ST80 (37.1% vs. 4%) and ST78 (15.5% vs. 4%) compared to vanB VR-E. faecium, which showed the predominance of ST17 (48% vs. 11.3%). VRE. faecium ST80 isolates exhibited significantly higher rates of daptomycin MICs of 4 μg/ml (21.6% vs. 8.7% and 6.2% for ST17 and ST78, respectively), and higher tetracycline resistance (64.9% vs. 4.3% and 6.3%) compared to ST17 and ST78. Streptomycin resistance was highest in ST78 (68.8%) compared to ST80 and ST17 (27% and 21.7% respectively). Conclusions. In hematology, an increase in the frequency of VR-E. faecium was observed. Susceptibility to daptomycin, linezolid, and tigecycline was preserved among all studied VR-E. faecium. VR-E. faecium demonstrated significant clonal diversity and evolution during spread. Resistance profiles varied significantly among strains belonging to different STs.
- 28 December 2025
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 27 (3) , 359-368
Open AccessVancomycin-resistant Enterococcus faecium in hematology: susceptibility to antimicrobial agents and clonal diversity
Objective. To study the antimicrobial resistance and clonal diversity of vancomycin-resistant E. faecium in hematology. Materials and Methods. Vancomycin-resistant E. faecium (VR-E. faecium) isolated from the blood culture of patients in six hospitals of Russia (2005–2023). Antimicrobial susceptibility of VR-E. faecium were determined by serial broth micro dilution was (CLSI, 2024), to tigecycline assessed according to EUCAST, 2025. Vancomycin-resistance genes (vanA, vanB) in VR-E. faecium were detected by multiplex PCR. Genotyping of VR-E. faecium was performed by MLST. Results. During the study period, 465 strains of E. faecium were isolated from blood culture, of which 122 (26.3%) were VR-E. faecium. The detection rate of VR-E. faecium increased from 13.1% (2005– 2011) to 59% (2018–2023, p = 0.0015). The majority of VR-E. faecium had the vanA genes (79.5%), while the vanB genes were detected in 20.5% of VR-E. faecium. All VR-E. faecium were susceptibledose dependent to daptomycin. The daptomycin MIC value of 4 μg/ml was determined in 16.4% of VRE. faecium and increased to 20.7% in 2018–2023. One (0.8%) VR-E. faecium strain was resistant to linezolid. All VRE. faecium isolates remained susceptible to tigecycline. A total of 24 sequence types (STs) belonging to clonal complex CC17 were detected. The predominant sequence types were ST80 (30.3%), ST17 (18.9%), and ST78 (13.1%). In 2023, a new ST2470 was registered in the pubMLST database. From 2018 to 2023, the proportion of ST80 increased to 62.1%, while ST17 and ST78 decreased to 13.8% and 5.2% respectively. vanA VR-E. faecium significantly more often belonged to ST80 (37.1% vs. 4%) and ST78 (15.5% vs. 4%) compared to vanB VR-E. faecium, which showed the predominance of ST17 (48% vs. 11.3%). VRE. faecium ST80 isolates exhibited significantly higher rates of daptomycin MICs of 4 μg/ml (21.6% vs. 8.7% and 6.2% for ST17 and ST78, respectively), and higher tetracycline resistance (64.9% vs. 4.3% and 6.3%) compared to ST17 and ST78. Streptomycin resistance was highest in ST78 (68.8%) compared to ST80 and ST17 (27% and 21.7% respectively). Conclusions. In hematology, an increase in the frequency of VR-E. faecium was observed. Susceptibility to daptomycin, linezolid, and tigecycline was preserved among all studied VR-E. faecium. VR-E. faecium demonstrated significant clonal diversity and evolution during spread. Resistance profiles varied significantly among strains belonging to different STs.
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 108-117
Coagulase-negative staphylococci from blood cultures – infection or contamination?
Background. Coagulase-negative staphylococci (CoNS) are one of the leading causative agents of bloodstream infections. At the same time, CoNS are part of the normal skin flora and can contaminate blood culture samples taken from patients. Aim. To characterize episodes of bloodstream infection and blood culture contamination caused by CoNS in patients with hematological diseases. Materials and methods. The frequency of CoNS detection from blood cultures was analyzed in patients hospitalized at the National Medical Research Center for Hematology in Moscow from January 1, 2022 to December 31, 2022. Blood for microbiology testing was taken from a patient with fever ≥38 °C into two bottles (aerobic / anaerobic) simultaneously from a vein and a central venous catheter or only from a vein. Blood bottles were incubated in an automatic blood culture analyzer (BD BACTEC FX, Becton Dickinson). Isolation of CoNS from only one of two blood culture samples was considered contamination. Results. CoNS were isolated from blood cultures in 90 patients (48 men and 42 women, median age 45.5 years). A total of 101 episodes of CoNS isolation were recorded, of which infection was diagnosed in 32 (31.7 %) cases, including 20 (62.5 %) bloodstream infections and 12 (37.5 %) catheter-associated bloodstream infections, while contamination was identified in 69 (68.3 %) cases. CoNS blood culture contamination was significantly less frequent than infection in patients with leukopenia (50.7 % vs 78.1 %; p = 0.03). The median duration of continuous hospitalization was significantly longer in patients with infection than in those with contamination (40.5 vs 16 days; p = 0.02). A total of 102 CoNS strains were isolated; rarer species such as Staphylococcus capitis, S. caprae, and S. warneri were isolated only in contamination cases. The median time to the positive blood culture signal was significantly shorter in infections than in CoNS contamination (14 hours 25 minutes vs 22 hours 10 minutes; p 0.0001). Most patients (75 %) received vancomycin. No cases of attributable mortality were identified. Conclusion. A high frequency of CoNS blood culture contamination (68.3 %) was determined, highlighting the critical importance of proper blood collection technique for microbiological examination. In contrast to infection, longer incubation time in the analyzer, isolation outside leukopenia, and shorter hospitalization duration were associated with CoNS contamination.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 108-117
Open AccessCoagulase-negative staphylococci from blood cultures – infection or contamination?
Background. Coagulase-negative staphylococci (CoNS) are one of the leading causative agents of bloodstream infections. At the same time, CoNS are part of the normal skin flora and can contaminate blood culture samples taken from patients. Aim. To characterize episodes of bloodstream infection and blood culture contamination caused by CoNS in patients with hematological diseases. Materials and methods. The frequency of CoNS detection from blood cultures was analyzed in patients hospitalized at the National Medical Research Center for Hematology in Moscow from January 1, 2022 to December 31, 2022. Blood for microbiology testing was taken from a patient with fever ≥38 °C into two bottles (aerobic / anaerobic) simultaneously from a vein and a central venous catheter or only from a vein. Blood bottles were incubated in an automatic blood culture analyzer (BD BACTEC FX, Becton Dickinson). Isolation of CoNS from only one of two blood culture samples was considered contamination. Results. CoNS were isolated from blood cultures in 90 patients (48 men and 42 women, median age 45.5 years). A total of 101 episodes of CoNS isolation were recorded, of which infection was diagnosed in 32 (31.7 %) cases, including 20 (62.5 %) bloodstream infections and 12 (37.5 %) catheter-associated bloodstream infections, while contamination was identified in 69 (68.3 %) cases. CoNS blood culture contamination was significantly less frequent than infection in patients with leukopenia (50.7 % vs 78.1 %; p = 0.03). The median duration of continuous hospitalization was significantly longer in patients with infection than in those with contamination (40.5 vs 16 days; p = 0.02). A total of 102 CoNS strains were isolated; rarer species such as Staphylococcus capitis, S. caprae, and S. warneri were isolated only in contamination cases. The median time to the positive blood culture signal was significantly shorter in infections than in CoNS contamination (14 hours 25 minutes vs 22 hours 10 minutes; p 0.0001). Most patients (75 %) received vancomycin. No cases of attributable mortality were identified. Conclusion. A high frequency of CoNS blood culture contamination (68.3 %) was determined, highlighting the critical importance of proper blood collection technique for microbiological examination. In contrast to infection, longer incubation time in the analyzer, isolation outside leukopenia, and shorter hospitalization duration were associated with CoNS contamination.
- Open Access
- 1 January 2024
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 26 (1) , 4-13
Virulence genes in Enterococcus faecium and Enterococcus faecalis isolated from blood culture in haematological patients
Objective. To study virulence genes in E. faecium and E. faecalis isolated from the blood cultures of patients with hematological diseases. Materials and Methods. Virulence genes were studied in E. faecium and E. faecalis strains isolated from blood culture from hematological patients in four Russian hospitals (2002–2020). Susceptibility to vancomycin was determined by broth microdilution method (CLSI, 2022). Virulence genes (esp, hyl, asa1, cylA and gelE) in E. faecium and E. faecalis as well as vancomycin resistance genes (vanA, vanB and vanD) in Enterococcus spp. were detected by multiplex PCR. Results. A total of 551 Enterococcus spp. strains were studied, of them 440 (79.9%) were E. faecium and 111 (20.1%) E. faecalis. Resistance to vancomycin was detected in 86 (19.5%) E. faecium, of them 62 (72.1%) carried vanA and 24 (27.9%) vanB genes. One (1.1%) of 111 E. faecalis was vancomycinintermediate (MIC 16 μg/ml) with vanD gene. Virulence genes were detected in 86.2% of Enterococcus spp., significantly more often among E. faecalis (95.5%) compared to E. faecium (83.9%, p = 0.003). The predominant genes in E. faecium were esp (70.2%) and hyl (52.1%), the detection of the asa1, cylA and gelE genes was minimal. Other genes dominated in E. faecalis: gelE (66.7%), asa1 (65.8%), cylA (36.9%). Statistically significant differences between E. faecium and E. faecalis were determined for all studied virulence genes (p < 0.0001). A combination of three or more virulence genes was detected significantly more often among E. faecalis in comparison with E. faecium (45% vs. 2.5%, p < 0.0001), whereas the presence of one gene or their absence prevailed in E. faecium (40.2% vs. 17.1%, p < 0.0001; 16.1% vs. 4.5%, p = 0.003, respectively). When comparing the two study periods (2002–2010 and 2011–2020), E. faecalis showed a significant increase in the proportion of strains with a combination of three or more virulence genes from 33.3% to 55% (p = 0.03), in E. faecium – with one virulence gene (from 31.7% to 46.3%, p = 0.002) and no genes (from 6.6% to 23%, p < 0.0001). Conclusions. Differences in the frequency of detection of virulence genes and their spectrum have been identified between E. faecium and E. faecalis strains. Virulence genes are significantly more often detected in E. faecalis with a predominance of combinations of three or more genes.
- 1 January 2024
- Published by Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy in Clinical Microbiology and Antimicrobial Chemotherapy
- Vol. 26 (1) , 4-13
Open AccessVirulence genes in Enterococcus faecium and Enterococcus faecalis isolated from blood culture in haematological patients
Objective. To study virulence genes in E. faecium and E. faecalis isolated from the blood cultures of patients with hematological diseases. Materials and Methods. Virulence genes were studied in E. faecium and E. faecalis strains isolated from blood culture from hematological patients in four Russian hospitals (2002–2020). Susceptibility to vancomycin was determined by broth microdilution method (CLSI, 2022). Virulence genes (esp, hyl, asa1, cylA and gelE) in E. faecium and E. faecalis as well as vancomycin resistance genes (vanA, vanB and vanD) in Enterococcus spp. were detected by multiplex PCR. Results. A total of 551 Enterococcus spp. strains were studied, of them 440 (79.9%) were E. faecium and 111 (20.1%) E. faecalis. Resistance to vancomycin was detected in 86 (19.5%) E. faecium, of them 62 (72.1%) carried vanA and 24 (27.9%) vanB genes. One (1.1%) of 111 E. faecalis was vancomycinintermediate (MIC 16 μg/ml) with vanD gene. Virulence genes were detected in 86.2% of Enterococcus spp., significantly more often among E. faecalis (95.5%) compared to E. faecium (83.9%, p = 0.003). The predominant genes in E. faecium were esp (70.2%) and hyl (52.1%), the detection of the asa1, cylA and gelE genes was minimal. Other genes dominated in E. faecalis: gelE (66.7%), asa1 (65.8%), cylA (36.9%). Statistically significant differences between E. faecium and E. faecalis were determined for all studied virulence genes (p < 0.0001). A combination of three or more virulence genes was detected significantly more often among E. faecalis in comparison with E. faecium (45% vs. 2.5%, p < 0.0001), whereas the presence of one gene or their absence prevailed in E. faecium (40.2% vs. 17.1%, p < 0.0001; 16.1% vs. 4.5%, p = 0.003, respectively). When comparing the two study periods (2002–2010 and 2011–2020), E. faecalis showed a significant increase in the proportion of strains with a combination of three or more virulence genes from 33.3% to 55% (p = 0.03), in E. faecium – with one virulence gene (from 31.7% to 46.3%, p = 0.002) and no genes (from 6.6% to 23%, p < 0.0001). Conclusions. Differences in the frequency of detection of virulence genes and their spectrum have been identified between E. faecium and E. faecalis strains. Virulence genes are significantly more often detected in E. faecalis with a predominance of combinations of three or more genes.
- Open Access
- 30 May 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (2) , 87‑99
In vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and Pseudomonas aeruginosa isolated from blood culture from patients with hematological diseases: results of a multicenter study
Background. Activity against Gram negative bacteria, including Pseudomonas aeruginosa, is required for first line antibiotic therapy in patients with febrile neutropenia.Aim. To study in vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and P. aeruginosa strains in patients with bloodstream infection and hematologic diseases.Materials and methods. Susceptibility of cefepime / sulbactam and biapenem in comparison to anibiotics used for febrile neutropenia was studied among Escherichia coli (n = 100), Klebsiella pneumoniae (n = 100), Enterobacter cloacae complex (n = 30), and P. aeruginosa (n = 70) isolated from blood culture (2017–2021) from patients with hematological diseases and infection in 4 Russian hospitals. Activity was determined by broth microdilution method, interpretation was according to Clinical and Laboratory Standards Institute (CLSI, 2022) and European Committee on Antimicrobial Susceptibility Testing (EUCAST , 2022) criteria, for cefepime / sulbactam we used cefepime criteria. The values of the minimum inhibitory concentration (MIC), MIC50 and MIC90 were studied.Results. MIC90 of cefepime / sulbactam were lower in comparison with piperacillin / tazobactam for E. coli without extended spectrum beta-lactamase (ESBL) production (0.125 μg / mL vs 1 μg / mL), K. pneumoniae without ESBL-production (0.125 μg / mL vs 2 μg / mL), K. pneumoniae with ESBL-production (32 μg / mL vs 128 μg / mL) with comparable frequency of resistant strains. For P. aeruginosa, preference of cefepime / sulbactam over piperacillin / tazobactam were found both by lower MIC90 (8 μg / mL vs 32 μg / mL) and by lower frequency of resistant strains according to EUCAST criteria (4.3 % vs 25.7 %). The MIC90 values of cefepime / sulbactam compared to cefepime and ceftazidime were 4 times lower for K. pneumoniae with ESBL-production and for Enterobacter cloacea complex, 2–4 times lower for P. aeruginosa, 64 times lower for E. coli with ESBL production.Values of biapenem MIC90 for E. coli without and with ESBL-production (0.032 μg / mL) were in intermediate position between meropenem and imipenem; for K. pneumoniae without ESBL-production – identical to imipenem (0.064 μg / mL), for K. pneumoniae with ESBL – minimal (0.064 μg / mL) against imipenem and meropenem; for E. cloacae – comparable to meropenem (0.032 μg / mL). For P. aeruginosa without carbapenemase production, the MIC50 / MIC90 values of biapenem (0.125 / 16 μg / mL) were minimal compared to meropenem (0.25 / 64 μg / mL) and imipenem (0.5 / 64 μg / mL).Conclusion. The favorable in vitro activity of cefepime / sulbactam and biapenem are fully comply with the requirements for febrile neutropenia.
- 30 May 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (2) , 87‑99
Open AccessIn vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and Pseudomonas aeruginosa isolated from blood culture from patients with hematological diseases: results of a multicenter study
Background. Activity against Gram negative bacteria, including Pseudomonas aeruginosa, is required for first line antibiotic therapy in patients with febrile neutropenia.Aim. To study in vitro activity of cefepime / sulbactam and biapenem against Enterobacterales and P. aeruginosa strains in patients with bloodstream infection and hematologic diseases.Materials and methods. Susceptibility of cefepime / sulbactam and biapenem in comparison to anibiotics used for febrile neutropenia was studied among Escherichia coli (n = 100), Klebsiella pneumoniae (n = 100), Enterobacter cloacae complex (n = 30), and P. aeruginosa (n = 70) isolated from blood culture (2017–2021) from patients with hematological diseases and infection in 4 Russian hospitals. Activity was determined by broth microdilution method, interpretation was according to Clinical and Laboratory Standards Institute (CLSI, 2022) and European Committee on Antimicrobial Susceptibility Testing (EUCAST , 2022) criteria, for cefepime / sulbactam we used cefepime criteria. The values of the minimum inhibitory concentration (MIC), MIC50 and MIC90 were studied.Results. MIC90 of cefepime / sulbactam were lower in comparison with piperacillin / tazobactam for E. coli without extended spectrum beta-lactamase (ESBL) production (0.125 μg / mL vs 1 μg / mL), K. pneumoniae without ESBL-production (0.125 μg / mL vs 2 μg / mL), K. pneumoniae with ESBL-production (32 μg / mL vs 128 μg / mL) with comparable frequency of resistant strains. For P. aeruginosa, preference of cefepime / sulbactam over piperacillin / tazobactam were found both by lower MIC90 (8 μg / mL vs 32 μg / mL) and by lower frequency of resistant strains according to EUCAST criteria (4.3 % vs 25.7 %). The MIC90 values of cefepime / sulbactam compared to cefepime and ceftazidime were 4 times lower for K. pneumoniae with ESBL-production and for Enterobacter cloacea complex, 2–4 times lower for P. aeruginosa, 64 times lower for E. coli with ESBL production.Values of biapenem MIC90 for E. coli without and with ESBL-production (0.032 μg / mL) were in intermediate position between meropenem and imipenem; for K. pneumoniae without ESBL-production – identical to imipenem (0.064 μg / mL), for K. pneumoniae with ESBL – minimal (0.064 μg / mL) against imipenem and meropenem; for E. cloacae – comparable to meropenem (0.032 μg / mL). For P. aeruginosa without carbapenemase production, the MIC50 / MIC90 values of biapenem (0.125 / 16 μg / mL) were minimal compared to meropenem (0.25 / 64 μg / mL) and imipenem (0.5 / 64 μg / mL).Conclusion. The favorable in vitro activity of cefepime / sulbactam and biapenem are fully comply with the requirements for febrile neutropenia.
- Open Access
- 15 March 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (1) , 88-100
Risk of bloodstream infections in allogeneic hematopoietic cell transplant recipients according to gut mucosal colonization and fluoroquinolone implementation during neutropenia
Background. Higher rate of gram-negative bloodstream infections (BSI) have been recently documented from transplantation centers providing fluoroquinolone (FQ) prophylaxis.Aim. To define the incidence of BSI during neutropenia according to gut mucosal colonization with resistant gramnegative bacteria and FQ administration.Materials and methods. Of 284 allogeneic hematopoietic cell transplant recipients included in the study, 154 (54.2 %) were identified as colonized with resistant gram-negative bacteria, and 130 (45.8 %) patients as non-colonized. Resistant gram-negative bacteria included Enterobacterales with extended spectrum beta-lactamase production, carbapenem-resistant Enterobacterales, Stenotrophomonas maltophilia, and carbapenem-resistant strains of Pseudomonas aeruginosa. Colonized patients did not receive FQ prophylaxis (n = 147) except 7 patients who received FQ as sequential therapy due to residual inflammatory lung lesions. Among non-colonized patients 98 received FQ prophylaxis, whereas 32 did not.Results. Probability of gram-negative BSI (71.4 %; p 0.0001), and extended spectrum beta-lactamase-producing Enterobacterales BSI (57.1 %; p 0.0001) was significantly higher in colonized patients receiving FQ. No significant difference was found in probability of gram-positive BSI (p = 0.452). In multivariate analysis colonized patients with (hazard ratio (HR) 35.32; 95 % confidence interval (CI) 9.15–136.44; p 0.0001) or without FQ (HR 3.44; 95 % CI 1.15–10.31; p = 0.007), omission of FQ in non-colonized patients (HR 4.03; 95 % CI 1.08–15.00; p = 0.038), and active disease before allogeneic hematopoietic cell transplantation (HR 2.17; 95 % CI 1.03–4.63; p = 0.042) were associated with higher risk of gram-negative BSI, whereas mismatched unrelated donor transplantations were associated with higher gram-positive BSI risk (HR 3.84; 95 % CI 1.63–9.08; p = 0,009).Conclusion. Colonization with multiresistant gram-negative bacteria is a predictor of gram-negative BSI, including multiresistant pathogens, especially when FQ are prescribed during neutropenia, while in non-colonized patients FQ prophylaxis is an effective approach significantly reducing gram-negative BSI.
- 15 March 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (1) , 88-100
Open AccessRisk of bloodstream infections in allogeneic hematopoietic cell transplant recipients according to gut mucosal colonization and fluoroquinolone implementation during neutropenia
Background. Higher rate of gram-negative bloodstream infections (BSI) have been recently documented from transplantation centers providing fluoroquinolone (FQ) prophylaxis.Aim. To define the incidence of BSI during neutropenia according to gut mucosal colonization with resistant gramnegative bacteria and FQ administration.Materials and methods. Of 284 allogeneic hematopoietic cell transplant recipients included in the study, 154 (54.2 %) were identified as colonized with resistant gram-negative bacteria, and 130 (45.8 %) patients as non-colonized. Resistant gram-negative bacteria included Enterobacterales with extended spectrum beta-lactamase production, carbapenem-resistant Enterobacterales, Stenotrophomonas maltophilia, and carbapenem-resistant strains of Pseudomonas aeruginosa. Colonized patients did not receive FQ prophylaxis (n = 147) except 7 patients who received FQ as sequential therapy due to residual inflammatory lung lesions. Among non-colonized patients 98 received FQ prophylaxis, whereas 32 did not.Results. Probability of gram-negative BSI (71.4 %; p 0.0001), and extended spectrum beta-lactamase-producing Enterobacterales BSI (57.1 %; p 0.0001) was significantly higher in colonized patients receiving FQ. No significant difference was found in probability of gram-positive BSI (p = 0.452). In multivariate analysis colonized patients with (hazard ratio (HR) 35.32; 95 % confidence interval (CI) 9.15–136.44; p 0.0001) or without FQ (HR 3.44; 95 % CI 1.15–10.31; p = 0.007), omission of FQ in non-colonized patients (HR 4.03; 95 % CI 1.08–15.00; p = 0.038), and active disease before allogeneic hematopoietic cell transplantation (HR 2.17; 95 % CI 1.03–4.63; p = 0.042) were associated with higher risk of gram-negative BSI, whereas mismatched unrelated donor transplantations were associated with higher gram-positive BSI risk (HR 3.84; 95 % CI 1.63–9.08; p = 0,009).Conclusion. Colonization with multiresistant gram-negative bacteria is a predictor of gram-negative BSI, including multiresistant pathogens, especially when FQ are prescribed during neutropenia, while in non-colonized patients FQ prophylaxis is an effective approach significantly reducing gram-negative BSI.
- Open Access
- 9 March 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (2) , 204-213
Post-engraftment Bloodstream Infections After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Association with Mortality
Akhmedov M, et al. Infect Chemother. 2023 Mar;55:e9. https://doi.org/10.3947/ic.2022.0146
- 9 March 2023
- Published by XMLink in Infection & Chemotherapy
- Vol. 55 (2) , 204-213
Open AccessPost-engraftment Bloodstream Infections After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Association with Mortality
Akhmedov M, et al. Infect Chemother. 2023 Mar;55:e9. https://doi.org/10.3947/ic.2022.0146
- 9 May 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (3) , e13842
Incidence, etiology, risk factors, and outcomes of pre‐engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation
Introduction: With an increasing number of allogeneic hematopoietic cell transplantations (allo‐HCT) bloodstream infections (BSI) are still among the most common and serious complications. This study aimed to analyze the incidence, etiology, risk factors, and outcomes of pre‐engraftment BSI after the first and the second allo‐HCT.Materials and methods: This is a retrospective study of 284 patients who underwent the first allo‐HCT and 37 patients after the second allo‐HCT at the National Research Center for Hematology in Moscow, Russia, from January 2018 till September 2021.Results: Cumulative incidence of pre‐engraftment BSI was 29.9% after the first allo‐HCT and 35.1% after the second (p = .805). The median time to the first BSI was 9 days (range 0–61 days) after the first and 16 days (range 1–28 days) after the second allo‐HCT (p = .014). A total of 113 pathogens were isolated during 94 BSI episodes after the first allo‐HCT (gram‐negative bacteria 52.2%; gram‐positive bacteria 47.7%). Fourteen pathogens were isolated during 14 BSI episodes after the second allo‐HCT (gram‐negative bacteria 50.0%; gram‐positive bacteria 50.0%). The only significant difference was found in the rate of carbapenem‐resistant gram‐negative bacteria, which was higher after the second allo‐HCT compared to the first (57.1% vs. 13.6%; p = .048).Mismatched unrelated donor (hazards ratio [HR] 3.01; 95% confidence interval [CI]: 1.62–5.60; p < .0001) and haploidentical donor transplantations (HR 1.84; 95% CI: 1.02–3.33; p = .042) were the only independent risk factors associated with the higher risk of pre‐engraftment BSI.Overall 30‐day survival after all BSI episodes was 94.4%. Survival was lower after BSI during the second allo‐HCT compared to the first (71.4% vs. 97.9%; p < .0001), particularly after BSI was caused by carbapenem‐resistant gram‐negative bacteria (25.0% vs. 100.0%; p = .0023). The non‐relapse mortality rate at day +60 was 4.0%, and the risk was highly associated with primary graft failure (HR 9.62; 95% CI: 1.33–71.43), second allo‐HCT (HR 6.80; 95% CI: 1.36–34.48), and pre‐engraftment BSI caused by carbapenem‐resistant gram‐negative bacteria (HR 32.11; 95% CI: 4.91–210.15).Conclusions: Pre‐engraftment BSI is still a common complication after allo‐HCT, particularly after mismatched unrelated and haploidentical donor transplantations. BSI incidence was slightly higher after the second allo‐HCT with a significantly higher rate of carbapenem‐resistant BSI. Although pre‐engraftment BSI would generally follow a benign clinical course, survival was dramatically lower during the second allo‐HCT, especially after carbapenem‐resistant BSI.
- 9 May 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (3) , e13842
Incidence, etiology, risk factors, and outcomes of pre‐engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation
Introduction: With an increasing number of allogeneic hematopoietic cell transplantations (allo‐HCT) bloodstream infections (BSI) are still among the most common and serious complications. This study aimed to analyze the incidence, etiology, risk factors, and outcomes of pre‐engraftment BSI after the first and the second allo‐HCT.Materials and methods: This is a retrospective study of 284 patients who underwent the first allo‐HCT and 37 patients after the second allo‐HCT at the National Research Center for Hematology in Moscow, Russia, from January 2018 till September 2021.Results: Cumulative incidence of pre‐engraftment BSI was 29.9% after the first allo‐HCT and 35.1% after the second (p = .805). The median time to the first BSI was 9 days (range 0–61 days) after the first and 16 days (range 1–28 days) after the second allo‐HCT (p = .014). A total of 113 pathogens were isolated during 94 BSI episodes after the first allo‐HCT (gram‐negative bacteria 52.2%; gram‐positive bacteria 47.7%). Fourteen pathogens were isolated during 14 BSI episodes after the second allo‐HCT (gram‐negative bacteria 50.0%; gram‐positive bacteria 50.0%). The only significant difference was found in the rate of carbapenem‐resistant gram‐negative bacteria, which was higher after the second allo‐HCT compared to the first (57.1% vs. 13.6%; p = .048).Mismatched unrelated donor (hazards ratio [HR] 3.01; 95% confidence interval [CI]: 1.62–5.60; p < .0001) and haploidentical donor transplantations (HR 1.84; 95% CI: 1.02–3.33; p = .042) were the only independent risk factors associated with the higher risk of pre‐engraftment BSI.Overall 30‐day survival after all BSI episodes was 94.4%. Survival was lower after BSI during the second allo‐HCT compared to the first (71.4% vs. 97.9%; p < .0001), particularly after BSI was caused by carbapenem‐resistant gram‐negative bacteria (25.0% vs. 100.0%; p = .0023). The non‐relapse mortality rate at day +60 was 4.0%, and the risk was highly associated with primary graft failure (HR 9.62; 95% CI: 1.33–71.43), second allo‐HCT (HR 6.80; 95% CI: 1.36–34.48), and pre‐engraftment BSI caused by carbapenem‐resistant gram‐negative bacteria (HR 32.11; 95% CI: 4.91–210.15).Conclusions: Pre‐engraftment BSI is still a common complication after allo‐HCT, particularly after mismatched unrelated and haploidentical donor transplantations. BSI incidence was slightly higher after the second allo‐HCT with a significantly higher rate of carbapenem‐resistant BSI. Although pre‐engraftment BSI would generally follow a benign clinical course, survival was dramatically lower during the second allo‐HCT, especially after carbapenem‐resistant BSI.
- Open Access
- 29 January 2022
- Published by Publishing House ABV Press in Oncohematology
- Vol. 17 (1) , 121-134
Bloodstream infections in different stage of reconstitution after first allogeneic hematopoietic stem cell transplantation
Background. Bloodstream infections (BSI) are common after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The objective of study was to analyze pre- and post-engraftment BSI.Materials and methods. From January 2018 till May 2021242 patients after first allo-HSCT were enrolled in the study. Median age was 35 (17–65) years. The majority of transplants were done for acute leukemias (71.9 %) in remission (91.7 %) with reduced-intensity conditioning regimens (71.5 %) and peripheral blood stem cells (74.4 %) as a graft source.Results. Of 242 patients 95 (39.2 %) developed BSI: 79 (83.2 %) developed 1 BSI episode, 16 (16.8 %) – 2 or more. Overall 113 BSI episodes were registered: 94 (82.7 %) were caused by single microorganism, 19 (17.3 %) were polymicrobial. Probability of pre-engraftment BSI was 31.0 %, post-engraftment – 11.8 %. In total 134 microorganisms were identified: 61.2 % – gram-negative and 38.8 % – gram-positive bacteria. Gram-negative BSI rate was significantly higher during post-engraftment compared to pre-engraftment phase (57.7 % vs. 70.3 %; р = 0.008). Major risk factor for pre-engraftment BSI was mismatched unrelated allo-HSCTs (hazard ratio (HR) 2.55; 95 % confidence interval (CI) 1.32–4.91; р = 0.03), for post-engraftment BSI – secondary poor graft function (HR 21.70; 95 % CI 7.95–59.24; р 0.0001) and graft failure (HR 21.55; 95 % CI 6.27–74.08; р 0.0001), and gut graft-versus-host disease (HR 12.90; 95 % CI 5.77–28.80; р 0.0001). Thirty-day survival after each BSI episode was 90.3 % and was significantly lower in patients with post-engraftment BSI compared to pre-engraftment (71.9 % vs. 97.5 %; р 0.0001).Conclusion. Gram-negative bacteria prevailed in the etiology of BSI. The main risk factors for pre-engraftment BSI was allo-HSCT from mismatched unrelated donors, for post-engraftment BSI – secondary poor graft function and graft failure. Post-engraftment BSI is associated with worse prognosis.
- 29 January 2022
- Published by Publishing House ABV Press in Oncohematology
- Vol. 17 (1) , 121-134
Open AccessBloodstream infections in different stage of reconstitution after first allogeneic hematopoietic stem cell transplantation
Background. Bloodstream infections (BSI) are common after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The objective of study was to analyze pre- and post-engraftment BSI.Materials and methods. From January 2018 till May 2021242 patients after first allo-HSCT were enrolled in the study. Median age was 35 (17–65) years. The majority of transplants were done for acute leukemias (71.9 %) in remission (91.7 %) with reduced-intensity conditioning regimens (71.5 %) and peripheral blood stem cells (74.4 %) as a graft source.Results. Of 242 patients 95 (39.2 %) developed BSI: 79 (83.2 %) developed 1 BSI episode, 16 (16.8 %) – 2 or more. Overall 113 BSI episodes were registered: 94 (82.7 %) were caused by single microorganism, 19 (17.3 %) were polymicrobial. Probability of pre-engraftment BSI was 31.0 %, post-engraftment – 11.8 %. In total 134 microorganisms were identified: 61.2 % – gram-negative and 38.8 % – gram-positive bacteria. Gram-negative BSI rate was significantly higher during post-engraftment compared to pre-engraftment phase (57.7 % vs. 70.3 %; р = 0.008). Major risk factor for pre-engraftment BSI was mismatched unrelated allo-HSCTs (hazard ratio (HR) 2.55; 95 % confidence interval (CI) 1.32–4.91; р = 0.03), for post-engraftment BSI – secondary poor graft function (HR 21.70; 95 % CI 7.95–59.24; р 0.0001) and graft failure (HR 21.55; 95 % CI 6.27–74.08; р 0.0001), and gut graft-versus-host disease (HR 12.90; 95 % CI 5.77–28.80; р 0.0001). Thirty-day survival after each BSI episode was 90.3 % and was significantly lower in patients with post-engraftment BSI compared to pre-engraftment (71.9 % vs. 97.5 %; р 0.0001).Conclusion. Gram-negative bacteria prevailed in the etiology of BSI. The main risk factors for pre-engraftment BSI was allo-HSCT from mismatched unrelated donors, for post-engraftment BSI – secondary poor graft function and graft failure. Post-engraftment BSI is associated with worse prognosis.
- Open Access
- 14 April 2021
- Published by Publishing House ABV Press in Oncohematology
- Vol. 16 (1) , 54-63
Antimicrobial resistance of Enterococcus faecium and Enterococcus faecalis, isolated from blood culture of patients with hematological malignancies during different study periods
Objective: to determine antimicrobial resistance of Enterococcus faecium and Enterococcus faecalis isolated from blood culture of hematological patients during different study periods.Materials and methods. Antimicrobial susceptibility of Enterococcus spp., collected as part of the multicenter study was tested by the broth microdilution method (USA Clinical and Laboratory Standards Institute (CLSI), 2018), to daptomycin by Etest (bioMeriéux, France). High-level gentamicin resistance (HLGR) and high-level streptomycin resistance (HLSR) was performed by the agar dilution method (CLSI (Oxoid, UK), 2018).Results. The susceptibility of 366 E. faecium (157 in 2002-2009 and 209 in 2010-2017) and 86 E. faecalis (44 in 20022009 and 42 in 2010-2017) was studied. In the second study period (2010-2017) the rise of vancomycin-resistant E. faecium (VREF) increased from 8.3 % to 23.4 % (p = 0.0001), and two linezolid-resistant (LREF) were identified. All VREF and LREF remained susceptible to daptomycin and tigecycline. The rate of susceptible to tetracycline E. faecium remained the same (73.9 and 74.6 %), and an increase in susceptibility to chloramphenicol (74.5 and 82.3 %) was observed. Susceptibility of E. faecium to tetracycline was detected with almost the same rate and in a part of isolates, the increase of susceptibility to chloramphenicol was registered during the analyzed periods. The rise of E. faecium susceptible to HLGR and HLSR has increased significantly in 2010-2017 compared to 2002-2009. Erythromycin, levofloxacin, ampicillin and penicillin had the least activity against E. faecium (less than 5 %).All E. faecalis were susceptible to tigecycline, linezolid, and teicoplanin. Only one of E. faecalis had intermediate resistance to vancomycin. High susceptibility to ampicillin in E. faecalis remained unchanged (97.7 and 97.6 %, respectively). In the second period of the study the rise of susceptible E. faecalis decreased significantly to penicillin (from 97.7 % to 76.2 %), to levofloxacin (from 59.1 % to 31 %), to HLSR (from 52.3 % до 31 %), and to HLGR (from 47.7 % to 26.2 %), remained unchanged to chloramphenicol (52.3 % and 50 %) and was minimal to erythromycin and tetracycline.Conclusion. The study demonstrated higher rates of antibiotic resistance among E. faecium, which consisted of an increase in VREF and the appearance of linezolid-resistant strains. High susceptibility to ampicillin remained in E. faecalis, but there was an increase in resistance to penicillin and aminoglycosides.
- 14 April 2021
- Published by Publishing House ABV Press in Oncohematology
- Vol. 16 (1) , 54-63
Open AccessAntimicrobial resistance of Enterococcus faecium and Enterococcus faecalis, isolated from blood culture of patients with hematological malignancies during different study periods
Objective: to determine antimicrobial resistance of Enterococcus faecium and Enterococcus faecalis isolated from blood culture of hematological patients during different study periods.Materials and methods. Antimicrobial susceptibility of Enterococcus spp., collected as part of the multicenter study was tested by the broth microdilution method (USA Clinical and Laboratory Standards Institute (CLSI), 2018), to daptomycin by Etest (bioMeriéux, France). High-level gentamicin resistance (HLGR) and high-level streptomycin resistance (HLSR) was performed by the agar dilution method (CLSI (Oxoid, UK), 2018).Results. The susceptibility of 366 E. faecium (157 in 2002-2009 and 209 in 2010-2017) and 86 E. faecalis (44 in 20022009 and 42 in 2010-2017) was studied. In the second study period (2010-2017) the rise of vancomycin-resistant E. faecium (VREF) increased from 8.3 % to 23.4 % (p = 0.0001), and two linezolid-resistant (LREF) were identified. All VREF and LREF remained susceptible to daptomycin and tigecycline. The rate of susceptible to tetracycline E. faecium remained the same (73.9 and 74.6 %), and an increase in susceptibility to chloramphenicol (74.5 and 82.3 %) was observed. Susceptibility of E. faecium to tetracycline was detected with almost the same rate and in a part of isolates, the increase of susceptibility to chloramphenicol was registered during the analyzed periods. The rise of E. faecium susceptible to HLGR and HLSR has increased significantly in 2010-2017 compared to 2002-2009. Erythromycin, levofloxacin, ampicillin and penicillin had the least activity against E. faecium (less than 5 %).All E. faecalis were susceptible to tigecycline, linezolid, and teicoplanin. Only one of E. faecalis had intermediate resistance to vancomycin. High susceptibility to ampicillin in E. faecalis remained unchanged (97.7 and 97.6 %, respectively). In the second period of the study the rise of susceptible E. faecalis decreased significantly to penicillin (from 97.7 % to 76.2 %), to levofloxacin (from 59.1 % to 31 %), to HLSR (from 52.3 % до 31 %), and to HLGR (from 47.7 % to 26.2 %), remained unchanged to chloramphenicol (52.3 % and 50 %) and was minimal to erythromycin and tetracycline.Conclusion. The study demonstrated higher rates of antibiotic resistance among E. faecium, which consisted of an increase in VREF and the appearance of linezolid-resistant strains. High susceptibility to ampicillin remained in E. faecalis, but there was an increase in resistance to penicillin and aminoglycosides.
- Open Access
- 11 September 2020
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 19 (4) , 38-47
Genotyping by Random Amplified Polymorphic DNA Assay of Acinetobacter baumannii Isolated from Blood Culture of Patients with Hematological Malignancies
Молекулярно-генетическое типирование Acinetobacter baumannii, выделенных из гемокультуры больных опухолями системы крови, методом ПЦР случайных полиморфных фрагментов ДНК
- 11 September 2020
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 19 (4) , 38-47
Open AccessGenotyping by Random Amplified Polymorphic DNA Assay of Acinetobacter baumannii Isolated from Blood Culture of Patients with Hematological Malignancies
Молекулярно-генетическое типирование Acinetobacter baumannii, выделенных из гемокультуры больных опухолями системы крови, методом ПЦР случайных полиморфных фрагментов ДНК